What's new?

TGCT Support supports patients with video for Rare Disease Day

Watch here 

---

First Western US to open Phase 3 for Vimseltinib 

​Check it out here

---

---

---

Director of Giant Cell Tumor Programs at TGCT Support, Sydney Stern, gives an overview of TGCT for CheckRare

​                       Check it out!

---

---

AmMax Bio announces positive results during AMB-05X Phase 2 trial of local injections to the knee

                           Learn more here

---

---

DCC-3014 (Vimseltinib) launches its Phase 3 Trial

Learn more here

---

TGCT Support Launches Support Groups!

Check it out here

​

---

National Organization for Rare Diseases (NORD) updates their TGCT page
​
Check it out here

---

---

AmMax Bio Announces First Patient Enrolled in Phase 2 Trial of AMB-05X for Tenosynovial Giant Cell Tumor (TGCT)

Read more here

---

CancerCare® Publishes White Paper Highlighting Gaps in Education and Care for Patients with Tenosynovial Giant Cell Tumors (TGCT)

Read more here

---

DCC-3014 (vimseltinib) shows promise as a new selective treatment for TGCT

Read more here

---

New Clinical Trial from AmMax Bio for an intra-articular joint injection for TGCT patients

Read more here